2020
Prospective, randomized, double-blind, placebo-controlled evaluation of the Pharmacokinetics, Safety and Efficacy of Recombinant Antithrombin Versus Placebo in Preterm Preeclampsia
Paidas MJ, Tita ATN, Macones GA, Saade GA, Ehrenkranz RA, Triche EW, Streisand JB, Lam GK, Magann EF, Lewis DF, Dombrowski MP, Werner EF, Branch DW, Habli MA, Grotegut CA, Silver RM, Longo SA, Amon E, Cleary K, How HY, Novotny SR, Grobman WA, Whiteman VE, Wing DA, Scifres CM, Sibai BM. Prospective, randomized, double-blind, placebo-controlled evaluation of the Pharmacokinetics, Safety and Efficacy of Recombinant Antithrombin Versus Placebo in Preterm Preeclampsia. American Journal Of Obstetrics And Gynecology 2020, 223: 739.e1-739.e13. PMID: 32780999, DOI: 10.1016/j.ajog.2020.08.004.Peer-Reviewed Original ResearchMeSH KeywordsAdministration, IntravenousAdolescentAdultAntithrombin ProteinsCesarean SectionDelivery, ObstetricDouble-Blind MethodFemaleFetal DistressGestational AgeHumansInfant, Premature, DiseasesInfant, Small for Gestational AgeMiddle AgedNeonatal SepsisPerinatal MortalityPre-EclampsiaPregnancyPregnancy Trimester, SecondPregnancy Trimester, ThirdProspective StudiesRecombinant ProteinsYoung AdultConceptsRecombinant human antithrombinPreterm preeclampsiaExpectant managementMorbidity scoreHuman antithrombinPlacebo-controlled clinical trialPlacebo-controlled evaluationPlacebo-controlled trialMedian gestational ageMaternal complicationsVersus PlaceboFetal outcomesMaternal outcomesPreterm deliveryEndothelial dysfunctionSecondary outcomesSingleton pregnanciesStandard therapyLoading dosePrimary outcomeWeeks' gestationGestational ageContinuous infusionClinical trialsSaline infusion
2013
Exploring the Role of Antithrombin Replacement for the Treatment of Preeclampsia: A Prospective Randomized Evaluation of the Safety and Efficacy of Recombinant Antithrombin in Very Preterm Preeclampsia (PRESERVE‐1)
Paidas MJ, Sibai BM, Triche EW, Frieling J, Lowry S, Group T. Exploring the Role of Antithrombin Replacement for the Treatment of Preeclampsia: A Prospective Randomized Evaluation of the Safety and Efficacy of Recombinant Antithrombin in Very Preterm Preeclampsia (PRESERVE‐1). American Journal Of Reproductive Immunology 2013, 69: 539-544. PMID: 23444920, DOI: 10.1111/aji.12091.Peer-Reviewed Original ResearchConceptsProspective Randomized EvaluationAntithrombin replacementWeeks' gestationRandomized EvaluationRecombinant antithrombinTreatment of preeclampsiaRecombinant human ATExpectant managementPreterm preeclampsiaPrimary endpointMaternal indicationsGestational ageStudy enrollmentAT therapyPreeclampsia studyPreeclampsiaGestationHuman ATAT replacementPharmacokinetic activityAntithrombinEfficacySafetyLaboratory assaysDelivery
2012
Correction of Systematic Bias in Ultrasound Dating in Studies of Small-for-Gestational-Age Birth: An Example From the Iowa Health in Pregnancy Study
Harland K, Saftlas A, Wallis A, Yankowitz J, Triche E, Zimmerman M. Correction of Systematic Bias in Ultrasound Dating in Studies of Small-for-Gestational-Age Birth: An Example From the Iowa Health in Pregnancy Study. American Journal Of Epidemiology 2012, 176: 443-455. PMID: 22886591, PMCID: PMC3499119, DOI: 10.1093/aje/kws120.Peer-Reviewed Original ResearchConceptsLast menstrual periodUltrasound gestational ageGestational ageSGA birthEarly ultrasoundPreterm deliveryPopulation-based case-control studyFirst trimester vaginal bleedingFirst trimester prenatal careGestational age fetusesGestational-age birthsCase-control studyStandard guidelinesMultivariable linear regressionDifferent study populationsVaginal bleedingGestational durationSGA fetusesSGA subjectsPrenatal careMaternal ageMenstrual periodPregnancy StudyStudy populationUnadjusted modelsFetal growth and later maternal death, cardiovascular disease and diabetes
LYKKE JA, PAIDAS MJ, TRICHE EW, LANGHOFF‐ROOS J. Fetal growth and later maternal death, cardiovascular disease and diabetes. Acta Obstetricia Et Gynecologica Scandinavica 2012, 91: 503-510. PMID: 22372730, DOI: 10.1111/j.1600-0412.2011.01355.x.Peer-Reviewed Original ResearchMeSH KeywordsAdolescentAdultBirth WeightCardiovascular DiseasesCohort StudiesDenmarkDiabetes MellitusFemaleFetal DevelopmentFollow-Up StudiesHealth Status IndicatorsHumansInfant, NewbornMiddle AgedMortality, PrematurePregnancyProportional Hazards ModelsReference StandardsRegistriesRetrospective StudiesRiskYoung AdultConceptsSubsequent maternal deathIschemic heart diseaseFetal growthPonderal indexMaternal deathsStandardized birthweightHeart diseaseCardiovascular diseaseSubsequent mortalityCox proportional hazards modelFirst singleton deliverySmaller risk estimatesSubsequent diabetes mellitusRetrospective cohort studyProportional hazards modelCardiovascular morbidityPregnancy complicationsCohort studySingleton deliveriesDiabetes mellitusGestational ageLow birthweightPrimary exposureSubsequent riskEarly deathFetal growth and later maternal death, cardiovascular disease and diabetes
LYKKE J, PAIDAS M, TRICHE E, LANGHOFF‐ROOS J. Fetal growth and later maternal death, cardiovascular disease and diabetes. Acta Obstetricia Et Gynecologica Scandinavica 2012, no-no. DOI: 10.1111/j.1600-0412.2012.01355.x.Peer-Reviewed Original ResearchSubsequent maternal deathIschemic heart diseaseFetal growthPonderal indexMaternal deathsStandardized birthweightHeart diseaseCardiovascular diseaseSubsequent mortalityFirst singleton deliverySmaller risk estimatesSubsequent diabetes mellitusProportional hazards modelCardiovascular morbidityPregnancy complicationsSingleton deliveriesDiabetes mellitusGestational ageLow birthweightPrimary exposureSubsequent riskEarly deathHazards modelBirthweightPremature death
2009
Hypertensive Pregnancy Disorders and Subsequent Cardiovascular Morbidity and Type 2 Diabetes Mellitus in the Mother
Lykke JA, Langhoff-Roos J, Sibai BM, Funai EF, Triche EW, Paidas MJ. Hypertensive Pregnancy Disorders and Subsequent Cardiovascular Morbidity and Type 2 Diabetes Mellitus in the Mother. Hypertension 2009, 53: 944-951. PMID: 19433776, DOI: 10.1161/hypertensionaha.109.130765.Peer-Reviewed Original ResearchMeSH KeywordsAdultCardiovascular DiseasesCase-Control StudiesCohort StudiesDenmarkDiabetes Mellitus, Type 2FemaleHumansHypertension, Pregnancy-InducedIncidencePre-EclampsiaPregnancyPregnancy OutcomePregnancy RatePregnancy, High-RiskPremature BirthProbabilityProportional Hazards ModelsRegistriesSeverity of Illness IndexYoung AdultConceptsType 2 diabetes mellitusSubsequent type 2 diabetes mellitusHypertensive pregnancy disordersSubsequent cardiovascular eventsDiabetes mellitusGestational hypertensionSevere preeclampsiaPregnancy disordersSubsequent hypertensionCardiovascular eventsRegistry-based cohort studyConsecutive singleton deliveriesSubsequent cardiovascular morbidityCongestive heart failureIschemic heart diseaseCardiovascular morbidityPlacental abruptionPreterm deliveryThromboembolic eventsCohort studyMild preeclampsiaSingleton deliveriesHeart failureSubsequent thromboembolismGestational age
2008
204: Small and large for gestational age birthweight in offspring are risk factors for subsequent maternal cardiovascular morbidity and type 2 diabetes mellitus
Lykke J, Damm P, Paidas M, Triche E, Sibai B, Langhoff-Roos J. 204: Small and large for gestational age birthweight in offspring are risk factors for subsequent maternal cardiovascular morbidity and type 2 diabetes mellitus. American Journal Of Obstetrics And Gynecology 2008, 199: s68. DOI: 10.1016/j.ajog.2008.09.231.Peer-Reviewed Original Research
2003
Association of Maternal Caffeine Consumption with Decrements in Fetal Growth
Bracken MB, Triche EW, Belanger K, Hellenbrand K, Leaderer BP. Association of Maternal Caffeine Consumption with Decrements in Fetal Growth. American Journal Of Epidemiology 2003, 157: 456-466. PMID: 12615610, DOI: 10.1093/aje/kwf220.Peer-Reviewed Original ResearchConceptsMaternal caffeine consumptionIntrauterine growth retardationCaffeine consumptionBirth weightCreatinine increaseUrinary caffeineGrowth retardationFirst prenatal visitLarge prospective studiesLow birth weightMean birth weightImportant confounding factorsFetal hazardsPerinatal outcomesPreterm deliveryCreatinine levelsPregnancy outcomesPrenatal visitUrinary cotinineGestational ageSingleton livebirthsThird trimesterProspective studyFetal growthMedical records
2000
Abortion and Its Effect on Risk of Preeclampsia and Transient Hypertension
Eras J, Saftlas A, Triche E, Hsu C, Risch H, Bracken M. Abortion and Its Effect on Risk of Preeclampsia and Transient Hypertension. Epidemiology 2000, 11: 36-43. PMID: 10615841, DOI: 10.1097/00001648-200001000-00009.Peer-Reviewed Original ResearchConceptsRisk of preeclampsiaTransient hypertensionNulliparous womenDecreased riskMore abortionsPregnancy-related risk factorsHistory of abortionHypertensive disordersWeeks' gestationGestational ageSubsequent pregnancyPrenatal careRisk factorsObstetric practicePrior abortionMonths gestationPreeclampsiaHypertensionInduced abortionReproductive historyReferent groupProtective factorsGestationWomenAbortion